Literature DB >> 25052858

The variable phenotypes of KCNQ-related epilepsy.

Nicholas M Allen1, Maria Mannion, Judith Conroy, Sally A Lynch, Amre Shahwan, Bryan Lynch, Mary D King.   

Abstract

Mutations in KCNQ2 and KCNQ3 were originally described in infants with benign familial neonatal seizures (BFNS). Recently, KCNQ2 mutations have also been shown to cause epileptic encephalopathy. This report describes three infants carrying abnormalities of KCNQ2 and one infant with a KCNQ3 mutation. The different KCNQ2 abnormalities led to different phenotypes and included a novel intragenic duplication, c.419_430dup, in an infant with BFNS, a 0.761Mb 20q13.3 contiguous gene deletion in an infant with seizures at 3 months, and a recurrent de novo missense mutation c.881C>T in a neonate with "KCNQ2-encephalopathy." The mutation in KCNQ3, c.989G>A, was novel and occurred in an infant with BFNS. KCNQ-related seizures often present with tonic/clonic manifestations, cyanosis, or apnea. Certain genotype-phenotype correlations help predict outcome. Similarly affected family members suggests benign familial "KCNQ-related" epilepsy, whereas neonatal seizures with unexplained multifocal epileptiform discharges or burst suppression on electroencephalography, and acute abnormalities of the basal ganglia/thalami are suggestive of KCNQ2-encephalopathy, which is often sporadic. 20q13.33 contiguous gene deletion encompassing KCNQ2 may harbor atypical features depending on deletion size. Although the phenotype often guides direct targeted gene testing in these conditions, array CGH should also be considered in suspected sporadic or atypical familial cases to diagnose 20q13.33 deletion. Wiley Periodicals, Inc.
© 2014 International League Against Epilepsy.

Entities:  

Keywords:  Array CGH; CHRNA4; Encephalopathy; Epilepsy; KCNQ2; KCNQ3

Mesh:

Substances:

Year:  2014        PMID: 25052858     DOI: 10.1111/epi.12715

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  19 in total

1.  Response to Carbamazepine in KCNQ2 Related Early Infantile Epileptic Encephalopathy.

Authors:  Indar Kumar Sharawat; Ananthanarayanan Kasinathan; Jitendra Kumar Sahu; Naveen Sankhyan
Journal:  Indian J Pediatr       Date:  2018-12-05       Impact factor: 1.967

Review 2.  The genetics of the epilepsies.

Authors:  Christelle M El Achkar; Heather E Olson; Annapurna Poduri; Phillip L Pearl
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 3.  Epileptogenesis in neonatal brain.

Authors:  Anna-Maria Katsarou; Aristea S Galanopoulou; Solomon L Moshé
Journal:  Semin Fetal Neonatal Med       Date:  2017-12-23       Impact factor: 3.926

4.  Novel genetic causes for cerebral visual impairment.

Authors:  Daniëlle G M Bosch; F Nienke Boonstra; Nicole de Leeuw; Rolph Pfundt; Willy M Nillesen; Joep de Ligt; Christian Gilissen; Shalini Jhangiani; James R Lupski; Frans P M Cremers; Bert B A de Vries
Journal:  Eur J Hum Genet       Date:  2015-09-09       Impact factor: 4.246

5.  Clinical and genetic features of 13 Spanish patients with KCNQ2 mutations.

Authors:  Montesclaros Hortigüela; Ana Fernández-Marmiesse; Verónica Cantarín; Sofía Gouveia; Juan J García-Peñas; Carmen Fons; Judith Armstrong; Desirée Barrios; Felícitas Díaz-Flores; Pilar Tirado; María L Couce; Luis G Gutiérrez-Solana
Journal:  J Hum Genet       Date:  2016-08-18       Impact factor: 3.172

6.  Prevention of brain damage after traumatic brain injury by pharmacological enhancement of KCNQ (Kv7, "M-type") K+ currents in neurons.

Authors:  Fabio A Vigil; Eda Bozdemir; Vladislav Bugay; Sang H Chun; MaryAnn Hobbs; Isamar Sanchez; Shayne D Hastings; Rafael J Veraza; Deborah M Holstein; Shane M Sprague; Chase M Carver; Jose E Cavazos; Robert Brenner; James D Lechleiter; Mark S Shapiro
Journal:  J Cereb Blood Flow Metab       Date:  2019-07-04       Impact factor: 6.200

7.  Evidence for Dual Activation of IK(M) and IK(Ca) Caused by QO-58 (5-(2,6-Dichloro-5-fluoropyridin-3-yl)-3-phenyl-2-(trifluoromethyl)-1H-pyrazolol[1,5-a]pyrimidin-7-one).

Authors:  Chao-Liang Wu; Poyuan Fu; Hsin-Yen Cho; Tzu-Hsien Chuang; Sheng-Nan Wu
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

8.  Seizures Due to a KCNQ2 Mutation: Treatment with Vitamin B6.

Authors:  Emma S Reid; Hywel Williams; Polona Le Quesne Stabej; Chela James; Louise Ocaka; Chiara Bacchelli; Emma J Footitt; Stewart Boyd; Maureen A Cleary; Philippa B Mills; Peter T Clayton
Journal:  JIMD Rep       Date:  2015-10-08

Review 9.  Advancing epilepsy genetics in the genomic era.

Authors:  Candace T Myers; Heather C Mefford
Journal:  Genome Med       Date:  2015-08-25       Impact factor: 11.117

10.  KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients.

Authors:  John J Millichap; Kristen L Park; Tammy Tsuchida; Bruria Ben-Zeev; Lionel Carmant; Robert Flamini; Nishtha Joshi; Paul M Levisohn; Eric Marsh; Srishti Nangia; Vinodh Narayanan; Xilma R Ortiz-Gonzalez; Marc C Patterson; Phillip L Pearl; Brenda Porter; Keri Ramsey; Emily L McGinnis; Maurizio Taglialatela; Molly Tracy; Baouyen Tran; Charu Venkatesan; Sarah Weckhuysen; Edward C Cooper
Journal:  Neurol Genet       Date:  2016-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.